The role of transplantation in diffuse large b-cell lymphoma: The impact of rituximab plus chemotherapy in first-line and relapsed settings

Current Hematologic Malignancy Reports

Volumn 6, Issue 1, 2011, Pages 47-57

  Rodrigues, Celso Arrais ^a   Patah, Poliana Alves ^a   Novis, Yana A S ^a   Hosing, Chitra ^b   De Lima, Marcos ^c  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NONE

Author keywords

Diffuse large B cell lymphoma; Rituximab; Salvage chemotherapy; SCT; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER TRANSPLANTATION; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG DOSE ESCALATION; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PROGNOSIS; SALVAGE THERAPY; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79551471965     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0075-5     Document Type: Article

References (95)

1. JR Anderson JO Armitage DD Weisenburger 1998 Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locationsNon-Hodgkin's Lymphoma Classification Project Ann Oncol 9 717 720 1:STN:280:DyaK1cvhtFOmsQ%3D%3D 10.1023/A:1008265532487 9739436 (Pubitemid 28394156)
2. AA Alizadeh MB Eisen RE Davis, et al. 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 503 511 1:CAS:528:DC%2BD3cXht1Shtrg%3D 10.1038/35000501 10676951 (Pubitemid 30082188)
3. A Rosenwald G Wright WC Chan, et al. 2002 Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 346 1937 1947 10.1056/NEJMoa012914 12075054 (Pubitemid 34651353)
4. B Coiffier 2006 Monoclonal antibody as therapy for malignant lymphomas C R Biol 329 241 254 1:CAS:528:DC%2BD28XjvFSjsbg%3D 10.1016/j.crvi.2005.12.006 16644494
5. RI Fisher ER Gaynor S Dahlberg, et al. 1993 Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 1002 1006 1:STN:280:DyaK3s7ps1Kmtg%3D%3D 10.1056/NEJM199304083281404 7680764 (Pubitemid 23095683)
6. B Coiffier E Lepage J Briere, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 1:CAS:528:DC%2BD38XmslGgsw%3D%3D 10.1056/NEJMoa011795 11807147 (Pubitemid 34438862)
7. M Pfreundschuh AD Ho E Cavallin-Stahl, et al. 2008 Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study Lancet Oncol 9 435 444 10.1016/S1470-2045(08)70078-0 18400558
8. P Feugier A Van Hoof C Sebban, et al. 2005 Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 4117 4126 1:CAS:528:DC%2BD2MXmt1elsr0%3D 10.1200/JCO.2005.09.131 15867204 (Pubitemid 46211317)
9. LH Sehn J Donaldson M Chhanabhai, et al. 2005 Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia J Clin Oncol 23 5027 5033 1:CAS:528:DC%2BD2MXpsFWmtLs%3D 10.1200/JCO.2005.09.137 15955905 (Pubitemid 46224009)
10. T Philip C Guglielmi A Hagenbeek, et al. 1995 Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 1540 1545 1:STN:280:DyaK28%2FmslCgtQ%3D%3D 10.1056/NEJM199512073332305 7477169
11. F Cabanillas FB Hagemeister P McLaughlin, et al. 1987 Results of MIME salvage regimen for recurrent or refractory lymphoma J Clin Oncol 5 407 412 1:STN:280:DyaL2s7ktVajtQ%3D%3D 3819806
12. WS Velasquez F Cabanillas P Salvador, et al. 1988 Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) Blood 71 117 122 1:STN:280:DyaL1c%2FnvVemsQ%3D%3D 3334893
13. S Cortelazzo A Rambaldi A Rossi, et al. 2001 Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma Br J Haematol 114 333 341 1:CAS:528:DC%2BD3MXmsVyhu74%3D 10.1046/j.1365-2141.2001. 02955.x 11529852 (Pubitemid 32762232)
14. A Josting M Sieniawski JP Glossmann, et al. 2005 High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study Ann Oncol 16 1359 1365 1:STN:280:DC%2BD2MvlsVehug%3D%3D 10.1093/annonc/mdi248 15939712 (Pubitemid 41158482)
15. A Olivieri M Brunori D Capelli, et al. 2004 Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis Eur J Haematol 72 10 17 10.1046/j.0902-4441.2004.00171.x 14962257 (Pubitemid 38161107)
16. E Jantunen C Canals A Rambaldi, et al. 2008 Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry Haematologica 93 1837 1842 10.3324/haematol.13273 18838474
17. CH Weaver FB Petersen FA Appelbaum, et al. 1994 High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma J Clin Oncol 12 2559 2566 1:STN:280:DyaK2M%2FotFOqsQ%3D%3D 7989929
18. F Gutierrez-Delgado DG Maloney, et al. 2001 Autologous stem cell transplantation for non-Hodgkin's lymphoma: Comparison of radiation-based and chemotherapy-only preparative regimens Bone Marrow Transplant 28 455 461 1:STN:280:DC%2BD3MrksFejsQ%3D%3D 10.1038/sj.bmt.1703179 11593318 (Pubitemid 33072077)
19. JR Brown H Yeckes JW Friedberg, et al. 2005 Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma J Clin Oncol 23 2208 2214 1:CAS:528:DC%2BD2MXjsVyiu7g%3D 10.1200/JCO.2005.05.158 15753460 (Pubitemid 46218712)
20. C Tarella M Zanni M Magni, et al. 2008 Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey J Clin Oncol 26 3166 75 1:CAS:528:DC%2BD1cXptlKgtLo%3D 10.1200/JCO.2007.14.4204 18490650
21. A Cuttica F Zallio M Ladetto, et al. 2003 Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3 Cancer 98 983 92 1:CAS:528:DC%2BD3sXns1Sjs7k%3D 10.1002/cncr.11610 12942566 (Pubitemid 37022099)
22. A Olivieri G Santini C Patti, et al. 2005 Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG Ann Oncol 16 1941 8 1:STN:280:DC%2BD2MnisVOnsQ%3D%3D 10.1093/annonc/mdi399 16157621 (Pubitemid 41724284)
23. GW van Imhoff B van der Holt MA Mackenzie, et al. 2005 Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40 J Clin Oncol 23 3793 801 10.1200/JCO.2005.07.039 15809447
24. • Smith SD, Bolwell BJ, Rybicki LA, et al. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. Bone Marrow Transplant 2010 May 17 (Epub ahead of print). This retrospective study evaluates outcomes after ASCT for relapsed DLBCL and shows that ASCT may be equally effective in patients relapsing after first-line therapy including rituximab; it should remain the standard of care for relapsed DLBCL.
25. C Guglielmi F Gomez T Philip, et al. 1998 Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial J Clin Oncol 16 3264 9 1:STN:280:DyaK1cvltV2rsg%3D%3D 9779700
26. J Blay F Gomez C Sebban, et al. 1998 The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial Parma Group. Blood 92 3562 8 1:CAS:528:DyaK1cXnsVKlsLs%3D
27. PA Hamlin AD Zelenetz T Kewalramani, et al. 2003 Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma Blood 102 1989 96 1:CAS:528:DC%2BD3sXntlKku78%3D 10.1182/blood-2002-12- 3837 12676776 (Pubitemid 37122371)
28. E Jabbour N Peslin P Arnaud, et al. 2005 Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation Leuk Lymphoma 46 861 67 1:STN:280:DC%2BD2Mzmtl2muw%3D%3D 10.1080/10428190500054350 16019530 (Pubitemid 40959674)
29. LJ Costa IN Micallef DJ Inwards, et al. 2008 Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation Bone Marrow Transplant 41 715 20 1:STN:280:DC%2BD1c3mslyhtw%3D%3D 10.1038/sj.bmt.1705967 18195687 (Pubitemid 351587037)
30. •• Oliansky DM, Czuczman M, Fisher RI, et al. The Role Of Cytotoxic Therapy With Hematopoietic Stem Cell Transplantation In The Treatment Of Diffuse Large B-Cell Lymphoma: Update Of The 2001 Evidence-Based Review. Biol Blood Marrow Transplant 2010 Jul 22 (Epub ahead of print). This detailed review, organized by the American Society for Blood and Marrow Transplantation, includes evidence-based recommendations for treatment.
31. Zinzani PL, Broccoli A, Stefoni V, et al. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. Cancer 2010 Aug 24 (Epub ahead of print).
32. P Seam ME Juweid BD Cheson 2007 The role of FDG-PET scans in patients with lymphoma Blood 110 3507 3516 1:CAS:528:DC%2BD2sXhtlarurzF 10.1182/blood-2007-06-097238 17709603 (Pubitemid 350159614)
33. K Spaepen S Stroobants P Dupont, et al. 2001 Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18 F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18 F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19 414 419 1:STN:280:DC%2BD3M7nvVCqsA%3D%3D 11208833
34. G Jerusalem Y Beguin MF Fassotte, et al. 1999 Whole-body positron emission tomography using 18 F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging Blood 94 429 433 1:CAS:528:DyaK1MXksVemt7s%3D 10397709
35. B Schot G van Imhoff J Pruim, et al. 2003 Predictive value of early 18Ffluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma Br J Haematol 123 282 287 10.1046/j.1365-2141.2003.04593.x 14531910 (Pubitemid 37305063)
36. J-E Filmont J Czernin C Yap, et al. 2003 Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation Chest 124 608 613 10.1378/chest.124.2.608 12907550 (Pubitemid 37000141)
37. K Spaepen S Stroobants P Dupont, et al. 2003 Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation Blood 102 53 59 1:CAS:528:DC%2BD3sXltFemtLk%3D 10.1182/blood-2002-12-3842 12609836 (Pubitemid 36759635)
38. BW Schot JM Zijlstra WJ Sluiter, et al. 2007 Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma Blood 109 486 491 1:CAS:528:DC%2BD2sXivVykurg%3D 10.1182/blood-2005-11-006957 17003382 (Pubitemid 46105942)
39. BW Schot J Pruim GW van Imhoff, et al. 2006 The role of serial pretransplantation positron emission tomography in predicting progressive disease in relapsed lymphoma Haematologica. 91 490 495 16533726
40. E Vellenga M van Agthoven AJ Croockewit, et al. 2001 Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study Br J Haematol 114 319 26 1:STN:280:DC%2BD3MvptFKmtQ%3D%3D 10.1046/j.1365-2141. 2001.02926.x 11529850 (Pubitemid 32762230)
41. PE Goss FA Shepherd JG Scott, et al. 1991 Dexamethasone/ifosfamide/ cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study Ann Oncol 2 Suppl 1 43 6 2043497
42. P Schutt J Passon P Ebeling, et al. 2007 Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas Eur J Haematol 78 93 101 1:STN:280:DC%2BD2s7hvVensg%3D%3D 10.1111/j.1600-0609.2006.00796.x 17313557 (Pubitemid 46061391)
43. M Ng J Waters D Cunningham, et al. 2005 Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma Br J Cancer 92 1352 57 1:CAS:528: DC%2BD2MXjsVSjsbg%3D 10.1038/sj.bjc.6602514 15812553 (Pubitemid 40704999)
44. C Hosing MF Munsell JM Reuben, et al. 2010 A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CS F for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas J Blood Med 1 49 55 10.2147/JBM.S9846
45. C Hosing RM Saliba M Korbling, et al. 2006 High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma Leuk Lymphoma 47 1290 1294 1:CAS:528:DC%2BD28XhtFWksbrF 10.1080/10428190500468584 16923559 (Pubitemid 44269636)
46. IF Khouri RM Saliba C Hosing, et al. 2005 Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas J Clin Oncol 23 2240 7 1:CAS:528:DC%2BD2MXjsVyiu7Y%3D 10.1200/JCO.2005.08.012 15800314 (Pubitemid 46218716)
47. GA Kennedy SK Tey R Cobcroft, et al. 2002 Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review Br J Haematol 119 412 416 1:CAS:528:DC%2BD38XpsVygsbg%3D 10.1046/j.1365-2141.2002.03843.x 12406079 (Pubitemid 35365492)
48. E Vellenga WL van Putten MB van't Veer, et al. 2008 Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial Blood 111 537 543 1:CAS:528:DC%2BD1cXns1CgsA%3D%3D 10.1182/blood-2007-08-108415 17971487
49. A Martín E Conde M Arnan, et al. 2008 R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study Haematologica 93 1829 1836 10.3324/haematol.13440 18945747
50. Gisselbrecht C, Schmitz N, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL study [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:517.
51. TM Habermann EA Weller VA Morrison, et al. 2006 Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 3121 7 1:CAS:528:DC%2BD28XnslKhsL4%3D 10.1200/JCO.2005.05.1003 16754935 (Pubitemid 46638950)
52. C Haioun N Mounier JF Emile, et al. 2009 Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma Ann Oncol 20 1985 92 1:STN:280:DC%2BD1MjntFKqsQ%3D%3D 10.1093/annonc/mdp237 19567453 This large, prospective study compares the induction regimens ACE and ACVBP before HDT and ASCT for patients with poor-risk DLBCL
53. SM Horwitz RS Negrin KG Blume, et al. 2004 Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma Blood 103 777 83 1:CAS:528:DC%2BD2cXhtValtbY%3D 10.1182/blood-2003-04-1257 12907446 (Pubitemid 38129532)
54. P Tsirigotis L Dray IB Resnick, et al. 2010 Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma Ann Hematol 89 263 72 1:CAS:528:DC%2BC3cXpsVSitw%3D%3D 10.1007/s00277-009-0808-5 19693502
55. The International Non-Hodgkin's Lymphoma Prognostic Factors Project 1993 a predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 987 94 10.1056/NEJM199309303291402 (Pubitemid 23307906)
56. U Kaiser I Uebelacker U Abel, et al. 2002 Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma J Clin Oncol 20 4413 9 1:CAS:528: DC%2BD38XosFCjs7k%3D 10.1200/JCO.2002.07.075 12431962 (Pubitemid 35334751)
57. C Gisselbrecht E Lepage T Molina, et al. 2002 Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma J Clin Oncol 20 2472 79 1:CAS:528:DC%2BD38XksFakurs%3D 10.1200/JCO.2002.02.125 12011124 (Pubitemid 34525732)
58. M Martelli F Gherlinzoni A De Renzo, et al. 2003 Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in highrisk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial J Clin Oncol 21 1255 62 10.1200/JCO.2003.01.117 12663712 (Pubitemid 46606401)
59. N Milpied E Deconinck F Gaillard, et al. 2004 Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support N Engl J Med 350 1287 95 1:CAS:528:DC%2BD2cXisFyiur4%3D 10.1056/NEJMoa031770 15044639 (Pubitemid 38375363)
60. D Betticher G Martinelli J Radford, et al. 2006 Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL) Ann Oncol 17 1546 1552 1:STN:280:DC%2BD28rnsFyktg%3D%3D 10.1093/annonc/mdl153 16888080 (Pubitemid 44542042)
61. U Vitolo A Chiappella E Angelucci, et al. 2009 Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study Haematologica. 94 1250 8 1:CAS:528:DC%2BD1MXhtlanurrM 10.3324/haematol.2009.007005 19586937
62. B Glass M Kloess M Bentz, et al. 2006 Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma Blood 107 3058 64 1:CAS:528:DC%2BD28Xjs1Olurk%3D 10.1182/blood-2005-04-1570 16384932
63. N Schmitz M Kloess M Reiser, et al. 2006 Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma Cancer 106 136 45 1:CAS:528:DC%2BD28XptF2qsA%3D%3D 10.1002/cncr.21588 16331635 (Pubitemid 43032558)
64. Glass B, Ziepert M, Reiser M, et al. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol 2010, 21:2255-61. This prospective trial shows a significant improvement of outcome when rituximab is added to MegaCHOEP in young patients with high-risk DLBCL.
65. •• Schmitz N, Nickelsen M, Ziepert M, et al. Aggressive Chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young, high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]. Blood (ASH Annual Meeting Abstracts), Nov 2009, 114:Abstract 404. This abstract presents preliminary results of a randomized study that questions the role of autologous transplantation in this setting.
66. A Re M Michieli S Casari, et al. 2009 High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors Blood 114 1306 13 1:CAS:528:DC%2BD1MXhtVGhu7vN 10.1182/blood-2009-02-202762 19451551
67. A Krishnan SJ Forman 2010 Hematopoietic stem cell transplantation for AIDS-related malignancies Curr Opin Oncol 22 456 60 10.1097/CCO.0b013e32833d2cf0 20639760
68. JM Calvo-Villas A Martín E Conde n behalf of the Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperative group), et al. 2010 Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation Ann Oncol 21 1891 7 1:STN:280:DC%2BC3cjnvFWlsA%3D%3D 10.1093/annonc/mdq035 20231299 This retrospective analysis by the GEL/TAMO cooperative group describes better outcomes with the addition of rituximab to the salvage chemotherapy in patients with relapsed DLBCL after ASCT
69. O Paltiel C Rubinstein R Or, et al. 2003 Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma Bone Marrow Transplant 31 565 9 1:STN:280:DC%2BD3s7ntleltg%3D%3D 10.1038/sj.bmt.1703888 12692622 (Pubitemid 36546834)
70. RJ Jones RF Ambinder S Piantadosi GW Santos 1991 Evidence of graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 77 649 53 1:STN:280:DyaK3M7itV2ksg%3D%3D 1991174
71. R Chopra AH Goldstone R Pearce, et al. 1992 Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data J Clin Oncol 10 1690 5 1:STN:280:DyaK3s%2FhvFChuw%3D%3D 1403052
72. M De Lima KW van Besien SA Giralt, et al. 1997 Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma Bone Marrow Transplant 19 121 7 10.1038/sj.bmt.1700614 9116608
73. N Dhedin S Giraudier P Gaulard, et al. 1999 Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database Br J Haematol 107 154 61 1:STN:280:DyaK1MvltV2mtw%3D%3D 10.1046/j.1365-2141.1999. 01666.x 10520036 (Pubitemid 29500821)
74. PJ Bierman JW Sweetenham FR Loberiza Jr, et al. 2003 Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation J Clin Oncol 21 3744 53 10.1200/JCO.2003.08.054 12963703 (Pubitemid 46606228)
75. I Aksentijevich RJ Jones RF Ambinder, et al. 2006 Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma Biol Blood Marrow Transplant 12 965 72 10.1016/j.bbmt.2006.05.018 16920563
76. IF Khouri M Keating M Korbling, et al. 1998 Transplant-lite: induction of graft-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies J Clin Oncol 16 2817 24 1:STN:280:DyaK1czmvVCgsA%3D%3D 9704734
77. SP Robinson AH Goldstone S Mackinnon, et al. 2002 Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation Blood 100 4310 6 1:CAS:528:DC%2BD38XpsFCqs7w%3D 10.1182/blood-2001-11-0107 12393626 (Pubitemid 35429668)
78. MP Escalon RE Champlin RM Saliba, et al. 2004 Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation J Clin Oncol 22 2419 23 10.1200/JCO.2004.09.092 15197204 (Pubitemid 41115399)
79. K Branson R Chopra PD Kottaridis, et al. 2002 Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies J Clin Oncol 20 4022 31 10.1200/JCO.2002.11.088 12351600
80. RD Faulkner C Craddock JL Byrne, et al. 2004 BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients Blood 103 428 34 1:CAS:528:DC%2BD2cXmsFeqtg%3D%3D 10.1182/blood-2003-05-1406 12969983 (Pubitemid 38140069)
81. P Corradini A Dodero L Farina, et al. 2007 Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome Leukemia 21 2316 23 1:CAS:528:DC%2BD2sXht1WgsbbL 10.1038/sj.leu.2404822 17597807 (Pubitemid 350011704)
82. AR Rezvani L Norasetthada T Gooley, et al. 2008 Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience Br J Haematol. 143 395 403 10.1111/j.1365-2141.2008.07365.x 18759762
83. KJ Thomson EC Morris A Bloor, et al. 2009 Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma J Clin Oncol 27 426 32 10.1200/JCO.2008.17. 3328 19064981
84. A Sirvent N Dhedin M Michallet, et al. 2010 Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire Biol Blood Marrow Transplant 16 78 85 10.1016/j.bbmt.2009.09.002 19744569
85. Warlick ED, Tomblyn M, Cao Q, et al. Reduced intensity conditioning followed by related allografts in hematologic malignancies: Long term outcomes most successful in indolent and aggressive non-hodgkins lymphomas. Biol Blood Marrow Transplant. 2010 Oct 31. [Epub ahead of print].
86. CA Rodrigues G Sanz CG Brunstein, et al. 2009 Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation J Clin Oncol 27 256 63 10.1200/JCO.2007.15.8865 19064984
87. Rodrigues CA, Canals C, Brunstein C, et al. Comparison of outcomes after unrelated cord blood transplantation and matched unrelated donor RIC transplantation for lymphoid malignancies-A Eurocord-Netcord Group/Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study [abstract]. Blood (ASH Annual Meeting Abstracts), Nov 2009, 114:663.
88. HX Wang HM Yan J Liu, et al. 2009 Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement Leuk Lymphoma 50 1488 93 1:CAS:528:DC%2BD1MXhsFOrtb7O 10.1080/10428190903156745 19811326
89. C Cutler D Miklos HT Kim, et al. 2006 Rituximab for steroid-refractory chronic graft-versus-host disease Blood 108 756 62 1:CAS:528: DC%2BD28XntFehu7w%3D 10.1182/blood-2006-01-0233 16551963 (Pubitemid 44061381)
90. JN Winter DJ Inwards S Spies, et al. 2009 Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 27 1653 9 1:CAS:528:DC%2BD1MXltVOht78%3D 10.1200/JCO.2008.19.2245 19255322
91. AK Gopal JG Rajendran TA Gooley, et al. 2007 High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or =∈60 years old with relapsed or refractory B-cell lymphoma J Clin Oncol 25 1396 402 10.1200/JCO.2006.09.1215 17312330 (Pubitemid 46706888)
92. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:405.
93. Vacirca JL, Acs PI, Shimkus BJ, P. J. Rosen. Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2010, 28:15 s (suppl; abstr 8041). clinicaltrials.gov NCT00987493.
94. P Martín RR Furman J Ruan, et al. 2008 Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma Semin Hematol 45 126 32 10.1053/j.seminhematol.2008.02.007 18381108 (Pubitemid 351444841)
95. B Jena G Dotti LJ Cooper 2010 Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor Blood 116 1035 44 1:CAS:528:DC%2BC3cXhtFensbrO 10.1182/blood-2010-01-043737 20439624